Curanex Pharmaceuticals Stock (NASDAQ:CURX)

Ownership Financials Chart

Previous Close

$0.22

52W Range

$0.20 - $9.18

50D Avg

$0.29

200D Avg

$0.42

Market Cap

$6.18M

Avg Vol (3M)

$91.44K

Beta

-2.85

Div Yield

CURX Company Profile

Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Aug 26, 2025

Website

CURX Performance

CURX Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-4.24M	$-365.06K	$-19.30K
Net Income	$-4.23M	$-361.51K	$-19.20K
EBITDA	$-4.24M	$-290.39K	$-17.48K
Basic EPS	$-0.17	$-0.01	-
Diluted EPS	$-0.17	$-0.01	-

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
ASBP	Aspire Biopharma Holdings, Inc.
LGVN	Longeveron Inc.
DARE	Dare Bioscience, Inc.
CUPR	Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
CRIS	Curis, Inc.
BCTX	BriaCell Therapeutics Corp.
PULM	Pulmatrix, Inc.
LPTX	Leap Therapeutics, Inc.
PALI	Palisade Bio, Inc.